As winter starts to thaw, the momentum in Philadelphia’s life sciences community is only picking up. This week, the city hosted two major events—Philly Builds Bio+ and LSPA's Annual Dinner & Showcase—bringing together industry leaders, innovators, and changemakers. Despite market turbulence, the region’s biotech ecosystem continues to push forward.
This Tuesday, BioBuzz and uCity Square are co-hosting Philadelphia’s Push: Breaking Barriers in Rare Disease Research, a must-attend event highlighting breakthroughs and challenges in rare disease innovation. It’s set to be a powerful discussion bringing together leaders, researchers, and advocates driving change in the rare disease space.
In this edition, we’ll dive into key takeaways from the week, spotlight exciting developments, and keep you plugged into what’s next.
|
|
|
|
-
Avacta: Agreement to Sell Launch Diagnostics and a Corporate Update More
-
Incyte: Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) More
-
Prelude Therapeutics: Full Year 2024 Financial Results and Provides Program Outlook for 2025 More
-
The Noramco Group: Invests $25 Million in Halo Pharma’s Whippany Facility to Offer Sterile Injectable Manufacturing More
-
At $300M Kardigan Startup: Former MyoKardia Team Unveils Its First Drug, and It Comes From Ionis More
-
Roche: Overhaul Spark Gene Therapy Unit, Recording $2.4B Full Impairment More
-
Mineralys Therapeutics: Stock Price Explodes After Lorundrostat Study Results Release More
-
Verrica Pharmaceuticals: Fourth Quarter and Full 2024 Financial Results More
-
Endo and Mallinckrodt: To Merge in $6.7B Deal More
-
Endo: Divestiture of International Pharmaceuticals Business More
|
|
|
-
COEPTIS: NexGenAI Affiliates Partners With NUBURU Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan More
-
Incyte: Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura) in Patients With Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting More
-
Mineralys Therapeutics: Positive Topline Results From Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension More
-
NiKang Therapeutics: Completes Dosing of the First Cohort in a Phase 1 Study of NKT3964, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2 Degrader More
-
RiboX Therapeutics: First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation More
-
SFA Therapeutics: Positive Phase 1b Data of SFA-002 in Mild-to-Moderate Psoriasis More
-
Helius Medical Technologies: First Reimbursement by A Major Healthcare Provider for Its Portable Neuromodulation Stimulator Device More
-
Wistar Institute: Scientists Identify New Strategy to Fight Cancer Caused by Epstein-Barr Virus More
-
Aprea Therapeutics: Agreement With MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma More
-
Integral Molecular: Launches Paratope-PLUS, a CDR-Scanning Service to Support Robust Patent Claims and Antibody Engineering More
-
Creatv Bio: PD-L1 Measured by Blood Test Reveals Important Clinical Information More
-
Faeth Therapeutics and The GOG Foundation: Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer More
-
INOVIO: Promising Interim Results From Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19 More
-
Third Arc Bio: First Patient Dosed in Phase 1 Clinical Trial of Lead T Cell Engager ARC101 to Treat CLDN6 Positive Cancers More
|
|
|
|
|
|
|
-
Children's Hospital of Philadelphia: Cancer Researchers Elected to the 2025 Class of Fellows of the AACR Academy More
-
Madrigal: Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors More
-
Iovance: Expects to Add Hundreds of Jobs at Navy Yard Cell Therapy Center More
|
|
|
|
Website | LinkedIn
Ocugen, a fully integrated, patient-centric biotech company, is hiring for many roles including Head of Clinical Development and Vice President of Manufacturing & Supply.
Here are some other innovative companies in the region that are hiring:
-
Harmony Biosciences (Plymouth Meeting, PA) - A leading pharma company dedicated to innovative therapies for patients with rare neurological diseases. Check out jobs here>
-
Director, Medical Writing
-
Senior Director, Clinical Pharmacology
-
Senior Director, Business Development
-
Context Therapeutics (Philadelphia, PA) - A biopharma company advancing T cell engaging bispecific antibodies for solid tumors. Check out jobs here>
-
Head of Regulatory
-
Senior Director/VP, Data management
-
Director/Senior Director, Project Management
-
Cabaletta Bio (Philadelphia, PA) - A clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies here>
-
Director, Clinical Program Management
-
Director, Clinical Scientist
-
Senior Director, CMC Regulatory Affairs
-
VintaBio (Philadelphia, PA) - Viral Vector Manufacturing. Check out jobs here>
-
Century Therapeutics (Philadelphia, PA) - Century Therapeutics is an innovative biotechnology company that is building an industry leading allogeneic iPSC-derived cell therapy platform. Check out jobs here>
-
Scientific Director, Upstream Process
-
Senior Director, Clinical Development
-
CMMS Specialist
|
|
|
BioInnovation Series Stop #2: Philadelphia's Push: Breaking Barriers in Rare Disease Research
|
Building off our successful BioInnovation Series launch event in February, we’re continuing the momentum with our next session—this time focused on Rare Disease Innovation. Philadelphia is home to groundbreaking advancements in rare disease research and therapeutic development, but how do we ensure these innovations lead to lasting impact, growth, and better patient outcomes?
|
|
|
|
|
|
|
